R1 is F, Cl, —CN, or —CH3 R2 is Cl or —CH3 R3 is —C(CH3)2OH or —CH2CH2OH Ra is H or —CH3 each Rb is independently F, Cl, —CH3, and/or —OCH3 and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Brutons tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
